Cancer Genetics Inc. (NASDAQ: CGIX) is 23.47% higher on its value in year-to-date trading and has touched a low of $1.92 and a high of $10.39 in the current 52-week trading range. The CGIX stock was last observed hovering at around $2.92 in the last trading session, with the day’s gains setting it 0.5% off its average median price target of $90.00 for the next 12 months. It is also 96.2% off the consensus price target high of $90.00 offered by 1 analysts, but current levels are 96.2% higher than the price target low of $90.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $3.42, the stock is 26.32% and 31.28% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 5.92 million and changing 17.12% at the moment leaves the stock 5.06% off its SMA200. CGIX registered -36.55% loss for a year compared to 6-month loss of 19.16%. The firm has a 50-day simple moving average (SMA 50) of $2.5673 and a 200-day simple moving average (SMA200) of $3.3480.
The stock witnessed a 39.02% gain in the last 1 month and extending the period to 3 months gives it a -14.07%, and is 26.20% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 13.90% over the week and 10.51% over the month.
Cancer Genetics Inc. (CGIX) has around 110 employees, a market worth around $14.19M and $6.30M in sales. Profit margin for the company is -71.50%. Distance from 52-week low is 78.13% and -67.08% from its 52-week high. The company has generated returns on investments over the last 12 months (-59.00%).
Cancer Genetics Inc. (CGIX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Cancer Genetics Inc. (CGIX) is a “Hold”. 1 analysts offering their recommendations for the stock have an average rating of 3.00, where 1 rate it as a Hold and 0 think it is a “Overweight”. 0 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Cancer Genetics Inc. is expected to release its quarterly report on 05/18/2021 and quarterly earnings per share for the current quarter are estimated at $0 with sales reaching $10.77M over the same period.The EPS is expected to grow by 22.70% this year, but quarterly earnings will post 70.40% year-over-year. Quarterly sales are estimated to grow 40.50% in year-over-year returns.
Cancer Genetics Inc. (CGIX) Top Institutional Holders
16 institutions hold shares in Cancer Genetics Inc. (CGIX), with 305.29k shares held by insiders accounting for 7.49% while institutional investors hold 18.29% of the company’s shares. The shares outstanding are 4.09M, and float is at 3.51M with Short Float at 0.81%. Institutions hold 16.92% of the Float.
The top institutional shareholder in the company is Renaissance Technologies, LLC with over 0.19 million shares valued at $0.8 million. The investor’s holdings represent 4.73% of the CGIX Shares outstanding. As of Sep 29, 2020, the second largest holder is Blackrock Inc. with 36665.0 shares valued at $0.15 million to account for 0.90% of the shares outstanding. The other top investors are Acadian Asset Management which holds 18001.0 shares representing 0.44% and valued at over $74704.0, while Vanguard Group, Inc. (The) holds 0.26% of the shares totaling 10519.0 with a market value of $43653.0.
Cancer Genetics Inc. (CGIX): Who are the competitors?
The company’s main competitors (and peers) include Enzo Biochem Inc. (ENZ) that is trading 3.41% up over the past 12 months. Short interest in the company’s stock has risen 44.34% from the last report on Nov 12, 2020 to stand at a total of 15890.0 short shares sold with a short interest ratio of 0.03.